Early Stage Deals Still Wow? Innate Jumps on BMS Alliance
By Jennifer Boggs
Friday, July 8, 2011
During last week's BIO International Convention in Washington, panelists in a business development session discussed whether biotech firms can count on scoring major dollars by licensing early stage preclinical or Phase I programs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.